Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Kenneth I. Zheng, Feng Gao, Xiao-Bo Wang, Qing-Feng Sun, Ke-Hua Pan, Ting-Yao Wang, Hong-Lei Ma, Wen-Yue Liu, Jacob George, Ming-Hua Zheng

PII: S0026-0495(20)30108-6
DOI: https://doi.org/10.1016/j.metabol.2020.154244
Reference: YMETA 154244

To appear in: Metabolism

Received date: 2 April 2020
Accepted date: 17 April 2020

Please cite this article as: K.I. Zheng, F. Gao, X.-B. Wang, et al., Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease, Metabolism (2020), https://doi.org/10.1016/j.metabol.2020.154244

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.
Title:

Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Authors:

Kenneth I. Zheng¹#, Feng Gao²#, Xiao-Bo Wang³, Qing-Feng Sun⁴, Ke-Hua Pan⁵, Ting-Yao Wang⁶, Hong-Lei Ma¹, Wen-Yue Liu⁷, Jacob George⁸* and Ming-Hua Zheng¹,⁹,¹⁰*

Institution:

¹MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; ²Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; ³Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China; ⁴Department of Infectious Diseases, Ruian People's Hospital, Wenzhou, China; ⁵Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; ⁶Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; ⁷Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; ⁸Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia ⁹Institute of Hepatology, Wenzhou Medical University, Wenzhou, China; ¹⁰Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.

*Co-first author: Kenneth I. Zheng and Feng Gao.
*Co-corresponding Author:

Ming-Hua Zheng, MD, PhD

MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University; No. 2 Fuxue Lane, Wenzhou 325000, China.

E-mail: zhengmh@wmu.edu.cn; fax: (86) 577-55578522; tel: (86) 577-55579622.

Jacob George, MD, PhD

Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead 2145, NSW, Australia,

Ph: 61-2-88907705; Fx 61-2-96357582. Email: jacob.george@sydney.edu.au.

Guarantor of the article: Ming-Hua Zheng and Jacob George

List of Abbreviations

BMI, body mass index; CI, confidence intervals; COVID-19, coronavirus disease-2019; OR, odds ratio; IL-6, interleukin 6.

Number of tables and supplementary tables: 2/1

Number of figures: 0

Electronic word count: 920
Abstract

**Background & Aims:** Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity.

**Methods:** 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI greater than 25 kg/m².

**Results:** The presence of obesity in MAFLD patients was associated with a ~6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19-27.91, p=0.029). Notably, this association with obesity and COVID-19 severity remained
significant (adjusted-OR 6.32, 95% CI 1.16-34.54, p=0.033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia.

**Conclusions:** Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD.

**Keywords:**

COVID-19; SARS-CoV-2; obesity; MAFLD.
Introduction

Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020.[1] Preliminary data suggests that obesity may aggravate the severity of respiratory diseases and of COVID-19.[2] Patients with metabolic associated fatty liver disease (MAFLD),[3] formerly known as non-alcoholic fatty liver disease, are often obese and have additional metabolic risk factors which may translate to a greater risk from respiratory diseases.[4-7] It is currently not known whether MALFD patients are also more likely to have greater COVID-19 severity of illness. This study investigated the association between MAFLD and COVID-19 severity.

Methods

We consecutively enrolled 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years from three hospitals in Wenzhou, China (the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital, and Ruian People's Hospital) between January 1, 2020 and February 29, 2020. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria.[3] Sixty six COVID-19 patients with MAFLD were included in the analyses and were divided into two groups [those with obesity (n=45) and those without (n=21)]. All patients received standard treatment based on the COVID-19 Management Guidance (7th edition).[8] This study was approved by the local ethics review boards of all three hospitals. The requirement for written informed consent was waived for use of the
COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the management guideline.[8] Blood routine markers were analyzed at the central laboratory of respective hospital using standard methods by VITROS 5600 Integrated Immunodiagnostic System (VITROS 5600, Johnson, New Jersey, USA).

We collected demographic information and past medical history from all patients. Laboratory parameters were tested on the first day of hospital admission. Body weight and height were measured by trained examiners on admission. Body mass index (BMI) was calculated using the formula weight (kilograms) divided by height (meters) squared. Obesity was defined as BMI greater than 25 kg/m².[9] Diabetes, hypertension and dyslipidemia were diagnosed based on established criteria.[10] All patients denied a history of chronic obstructive or restrictive pulmonary disease.

Continuous variables are expressed as mean ± SD and compared using either the Student’s t-test for normally distributed variables or the Mann-Whitney test for non-normally distributed variables. Continuous variables were tested for normality using the Shapiro-Wilk test. Differences between categorical variables was examined...
with the chi-squared test or the Fisher’s exact test as appropriate. The association between obesity (as exposure) and COVID-19 severity (as the outcome) among MAFLD patients was assessed by binary logistic regression. Statistical analyses were two-sided and significance was set at \( p < 0.05 \). All statistical tests were performed using SPSS version 23.0 (SPSS Inc., Chicago, USA).

Results

The mean age of enrolled patients was 47 years and 74.2% were female. Table 1 shows the main clinical and biochemical characteristics of COVID-19 patients with MAFLD stratified by obesity status. Mean BMI for the non-obese and obese patients were 22.7 ±2.1 kg/m\(^2\) and 28.3 ±3.2 kg/m\(^2\), respectively. Compared with the non-obese group, obese patients had higher levels of aspartate aminotransferase, fasting blood glucose and LDL-cholesterol, and lower lymphocyte counts. Notably, MALFD patients that were obese had more severe COVID-19 disease (37.5% vs. 9.5%, \( p =0.021 \)).

As shown in Supplementary Table, there were 47 (71.2%) patients with non-severe COVID-19 and 19 (28.8%) with severe COVID-19. Compared to those with non-severe COVID-19, patients with severe disease were more obese (89.5% vs. 59.6%, \( p =0.021 \)). They were also more likely to be smokers (26.3% vs. 6.4%, \( p =0.038 \)), and had higher C-reactive protein concentrations (median 52.7 [IQR 33.5-74.9] vs. 18.3 [4.6-24.9], \( p <0.001 \)) and lower lymphocyte counts (median 1.0
As shown in Table 2, in the unadjusted logistic regression model with COVID-19 severity as the outcome, the presence of obesity in MAFLD patients was associated with a ~6-fold increased risk of severe COVID-19 illness (unadjusted OR 5.77, 95% CI 1.19-27.91, p=0.029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95%CI 1.16-34.54, p =0.033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia.

Discussion

Our results show that in MAFLD patients with laboratory-confirmed COVID-19, the presence of obesity markedly increases the risk of having severe illness. This association remained significant after adjusting for likely confounders.

We reported previously that obesity is associated with a nearly 3-fold increased risk for severe COVID-19 with a dose-effect relationship between increasing BMI and the proportion of patients with severe illness.[11] In the current analysis, the risk of severe illness in MAFLD patients with co-existing obesity was more than 6-fold greater after adjustment for confounders. These findings are distinct, suggesting that the risk of obesity to COVID-19 severity is significantly greater in those with MAFLD. However, the virological and physiological mechanisms underlying the relationship we observed is not clarified by the present data. Systemic inflammatory

[IQR 0.8-1.2] vs. 1.4 [1.1-1.7], p =0.005).
response syndrome, a common complication in severe COVID-19,[12] is promoted by the activation of CD14+ and CD16+ inflammatory monocytes producing a larger amount of interleukin (IL)-6 and other proinflammatory factors. This suggests IL-6 is a key proinflammatory factor that triggers the inflammatory “storm” in patients.[13] In MAFLD patients, particularly those with obesity, increased inflammatory activity in the liver and visceral fat is independently correlated with increased levels of IL-6,[14] which might have an additive/synergistic role in promoting greater severity of COVID-19. It is conceivable that the secretion of hepatokines for example, reduced adiponectin or the altered secretion of inflammatory lipid mediators in obese patients with MAFLD,[15] may also contribute to the current observations.

While this is the first multi-center study to investigate obesity as a possible risk factor for severe COVID-19 illness in patients with MAFLD, some limitations should be recognized. Patients included in our study did not undergo liver biopsy, thus COVID-19 severity in relation to liver histology could not be assessed. Waist circumference, a risk factor for MAFLD, was not measured in our patients, which precluded adjustment of this confounder. In addition, patients were of Asian ethnicity and thus the applicability of the results to other ethnic groups is uncertain. Additional studies will be needed to confirm these findings and to better understand the underlying mechanisms for why the association with obesity is greater in those with MAFLD.
In conclusion, our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD.

**Authors Contributions**

Study concept and design: Kenneth I. Zheng, Feng Gao and Ming-Hua Zheng

Acquisition of data: Xiao-Bo Wang, Qing-Feng Sun, Ke-Hua Pan, Ting-Yao Wang, Hong-Lei Ma

Analysis and interpretation of data: Fen Gao and Kenneth I. Zheng

Drafting of the manuscript: Kenneth I. Zheng, Feng Gao and Wen-Yue Liu

Critical revision of the manuscript for important intellectual content: Jacob George and Ming-Hua Zheng.

Study supervision: Ming-Hua Zheng

All authors contributed to the manuscript for important intellectual contents and approved the submission.

**Funding**

This work was supported by grants from the National Natural Science Foundation of China (81500665), High Level Creative Talents from Department of Public Health in Zhejiang Province and Project of New Century 551 Talent Nurturing in Wenzhou.

**Conflict of interest statement**

All authors declare no conflict of interest.
**References**

[1] WHO characterizes COVID-19 as a pandemic. Published March 13, 2020. Accessed March 18, 2020. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen).

[2] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.

[3] Eslam M, Newsome PN, Anstee QM, Targher G, Gómez MR, Zelber-Sagi S, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020.

[4] Arias-Loste MT, Fábrega E, López-Hoyos M, Crespo J. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2015;2015:319745.

[5] Lee CH, Choi SH, Chung GE, Park B, Kwak MS. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int. 2018;38:2091–100.

[6] Nseir WB, Mograbi JM, Amara AE, Abu Elheja OH, Mahamid MN. Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia. Qjm. 2019;112:95–9.

[7] Peng TC, Kao TW, Wu LW, Chen YJ, Chang YW, Wang CC, et al. Association Between Pulmonary Function and Nonalcoholic Fatty Liver Disease in the NHANES III Study. Medicine (Baltimore). 2015;94:e907.

[8] National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). 2020 [EB/OL]. 2020.03.03.

[9] Goda A, Masuyama T. Obesity and Overweight in Asian People. Circulation journal : official journal of the Japanese Circulation Society. 2016;80:2425–6.

[10] Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic medicine : a journal of the British Diabetic Association. 2006;23:469–80.

[11] Gao F, Zheng KI, Wang X-B, Sun Q-F, Pan K-H, Wang T-Y, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020.

[12] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

[13] Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020;8(1):1–7.

[14] van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48:449–57.

[15] Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, et al. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology. 2019.
Table legend

**Table 1.** Baseline characteristics of MAFLD patients with laboratory-confirmed COVID-19 according to obesity status.

**Table 2.** Multivariable-adjusted association between obesity (as exposure) and COVID-19 severity (as the outcome) in patients with MAFLD.

**Supplementary Table.** Baseline characteristics of MAFLD patients according to COVID-19 severity.
Table 1. Baseline characteristics of MAFLD patients with laboratory-confirmed COVID-19 according to obesity status.

|                                    | Overall N=66 | Without obesity N=21 | With obesity N=45 | P value |
|------------------------------------|--------------|----------------------|-------------------|---------|
| **Demographics**                   |              |                      |                   |         |
| Age, years, yrs, n (%):            |              |                      |                   |         |
| 18-44 yrs                          | 39 (59.1%)   | 15 (71.43%)          | 24 (53.33%)       | 0.207   |
| 45-64 yrs                          | 22 (33.3%)   | 6 (28.57%)           | 16 (35.56%)       |         |
| ≥65 yrs                            | 5 (7.6%)     | 0 (0.00%)            | 5 (11.11%)        |         |
| Female sex, n (%):                 | 17 (25.8%)   | 4 (19.05%)           | 13 (28.89%)       | 0.548   |
| Body mass index, kg/m²             | 26.5 ± 3.9   | 22.7 ± 2.1           | 28.3 ± 3.2        | <0.001  |
| **Coexisting disorders**           |              |                      |                   |         |
| Current smoker, n (%):             | 8 (12.1%)    | 2 (9.5%)             | 6 (13.3%)         | 0.659   |
| Type 2 diabetes, n (%):            | 16 (24.2%)   | 2 (9.5%)             | 14 (31.1%)        | 0.070   |
| Hypertension, n (%):               | 19 (28.8%)   | 3 (14.3%)            | 16 (35.6%)        | 0.089   |
| Dyslipidemia, n (%):               | 45 (68.2%)   | 14 (66.67%)          | 31 (68.89%)       | 0.857   |
| **Laboratory parameters**          |              |                      |                   |         |
| White blood cell count, x10⁹       | 4.9 (3.9-6.7)| 4.8 (3.8-6.3)        | 5.0 (4.1-6.7)     | 0.495   |
| >10 x10⁹, n (%):                   | 2 (3.0%)     | 0 (0.0%)             | 2 (4.4%)          | 0.511   |
| <4 x10⁹, n (%):                    | 17 (25.8%)   | 7 (33.3%)            | 10 (22.2%)        |         |
| Lymphocyte count, x10⁹             | 1.2 (0.9-1.6)| 1.4 (1.1-1.8)        | 1.1 (0.9-1.4)     | 0.040   |
| <1.5 x10⁹, n (%):                  | 47 (71.2%)   | 11 (52.4%)           | 36 (80.0%)        | 0.021   |
| C-reactive protein, mg/L           | 21.6 (8.1-47.3)| 18.3 (5.8-24.5)   | 25.3              | 0.097   |
| ≥10 mg/L, n (%):                   | 47 (71.2%)   | 13 (61.9%)           | 34 (75.6%)        | 0.382   |
| Alanine                            | 29.5         | 26.0                 | 30.0              | 0.150   |
| aminotransferase, U/L              | (24.0-62.5)  | (20.0-45.0)          | (24.0-65.0)       |         |
| >40 U/L, n (%):                    | 25 (37.9%)   | 6 (28.6%)            | 19 (42.2%)        | 0.415   |
| Aspartate                          | 31.5         | 25.0                 | 35.0              | 0.010   |
| aminotransferase, U/L              | (23.0-47.0)  | (21.0-33.0)          | (27.0-52.0)       |         |
| >40 U/L, n (%):                    | 20 (30.3%)   | 2 (9.5%)             | 18 (40.0%)        | 0.020   |
| Total bilirubin, μmol/L            | 13.3 (9.3-17.1)| 15.6              | 11.5              | 0.051   |
| Creatinine, μmol/L                 | 74.0         | 78.0                 | 74.0              | 0.401   |
| (65.5-83.0)                        |              |                      |                   |         |
| Fasting blood glucose, mmol/L      | 6.7 ± 2.3    | 5.8 ± 1.5            | 7.1 ± 2.6         | 0.047   |
| HbA1c, %                           | 1.5 ± 0.6    | 1.3 ± 0.6            | 1.5 ± 0.6         | 0.145   |
| Triglycerides, mmol/L              | 3.9 ± 0.9    | 3.7 ± 0.9            | 4.1 ± 0.9         | 0.086   |
| Total cholesterol, mmol/L          | 1.0 ± 0.3    | 1.1 ± 0.2            | 1.0 ± 0.3         | 0.255   |
mmol/L
HDL-cholesterol, mmol/L
  2.3 ± 0.9  2.0 ± 0.9  2.4 ± 0.8  0.074
LDL-cholesterol, mmol/L
  7.0 ± 1.1  5.7 ± 0.5  7.3 ± 1.1  0.032

COVID-19 severity, n (%)

|        | Non-severe | Severe |
|--------|------------|--------|
|        | 47 (71.2%) | 19 (28.8%) |
|        | 19 (90.5%) | 2 (9.5%) |
|        | 28 (62.2%) | 17 (37.8%) |

Data are expressed as mean ± SD, medians and inter-quartile range or percentage.
Table 2. Multivariable-adjusted association between obesity (as exposure) and COVID-19 severity (as the outcome) in patients with MAFLD.

|                      | OR   | 95% CI       | P value |
|----------------------|------|--------------|---------|
| Unadjusted           | 5.77 | 1.19-27.91   | 0.029   |
| Adjusted model I     | 6.25 | 1.23-31.71   | 0.027   |
| Adjusted model II    | 6.32 | 1.16-34.54   | 0.033   |

Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, smoking, type 2 diabetes, hypertension, and dyslipidemia.